- Hovione and iBET establish a new venture, ViSync Technologies, focused on addressing unmet needs in cell and gene therapy.
- ViSync aims to develop technologies for the delivery and stabilization of new modality therapies, headquartered in Lisbon, Portugal.
Hovione, a CDMO, and iBET have launched ViSync Technologies, a jointly owned venture based in the Lisbon area, Portugal. This collaboration aims to address technical gaps in the cell and gene therapy space. The company will leverage Hovione’s pharmaceutical development capabilities and iBET’s expertise in biotechnology to create innovative solutions for pharmaceutical companies.
The joint venture was established to focus on the delivery and stabilization of new modality therapies. Both partners see this as a key area where advancements can lead to improved drug development outcomes. ViSync’s primary goal is to develop technologies that will enhance the efficacy and stability of these therapies, a challenge many pharma companies face today.
Jean-Luc Herbeaux, CEO of Hovione, commented on the partnership: “We are delighted to join forces with iBET. By combining Hovione’s expertise in drug formulation, manufacturing, and scale-up with iBET’s deep understanding of new modalities, we aim to help pharma companies launch innovative medicines.” Paula Alves, CEO of iBET, echoed these sentiments, adding, “The creation of ViSync marks a significant milestone for iBET, positioning us to drive substantial advancements in new therapy development.”
ViSync Technologies will begin operations in Lisbon, Portugal, with the objective of delivering practical innovations for pharmaceutical firms globally, as the demand for cell and gene therapies continues to grow.
Overview of outsourcing trends 
